Adrián Fernández-De-La-Pradilla

Adrián Fernández-De-La-Pradilla

Auto-generated profile, based on publicly available information

Adrián Fernández-De-La-Pradilla

Departament de Química Física i Analítica, Universitat Jaume I, 12080 Castelló, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LALaura Agost-Beltrán
Laura Agost-Beltrán
SHSergio de la Hoz-Rodríguez
Sergio de la Hoz-Rodríguez
LBLledó Bou-Iserte
Lledó Bou-Iserte
SRSantiago Rodríguez
Santiago Rodríguez
AFAdrián Fernández-De-La-Pradilla
Adrián Fernández-De-La-Pradilla
FAFlorenci V. Gonzalez Adelantado
Florenci V. Gonzalez Adelantado
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.

8 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
LALaura Agost-Beltrán
Laura Agost-Beltrán
SHSergio de la Hoz-Rodríguez
Sergio de la Hoz-Rodríguez
LBLledó Bou-Iserte
Lledó Bou-Iserte
SRSantiago Rodríguez
Santiago Rodríguez
AFAdrián Fernández-De-La-Pradilla
Adrián Fernández-De-La-Pradilla
FAFlorenci V. Gonzalez Adelantado
Florenci V. Gonzalez Adelantado
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases like the main proteases of SARS-CoV and MERS-CoV were tested. Then a huge effort has been done by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead, and the second one is a diverse group including chemical compounds which do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.